At the recent Exosome Based Therapeutic Development Summit, ReNeuron’s new data demonstrated an improved competitive profile of its exosome platform beyond its tropism and other advantages. In addition, the platform now has a name – CustomEx™. The CustomEx™ exosome platform has now expanded its innate or potentially engineered tropism advantages further. Specifically, by showing improved exosome uptake in three tissue types and a higher level of siRNA delivery versus the HEK cellgenerated exosom ....
07 Oct 2022
ReNeuron Group Update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ReNeuron Group Update
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
07 Oct 2022 -
Author:
Andy Smith -
Pages:
4
At the recent Exosome Based Therapeutic Development Summit, ReNeuron’s new data demonstrated an improved competitive profile of its exosome platform beyond its tropism and other advantages. In addition, the platform now has a name – CustomEx™. The CustomEx™ exosome platform has now expanded its innate or potentially engineered tropism advantages further. Specifically, by showing improved exosome uptake in three tissue types and a higher level of siRNA delivery versus the HEK cellgenerated exosom ....